← All trials
NCT06574568
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Jun 30, 2027
- First posted
- Aug 28, 2024
- Last posted
- Sep 25, 2024
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Excyte Biopharma LtdLead sponsor
- Capital Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.